Lv1
50 积分 2024-08-07 加入
A first‐line regimen combining Bruton's tyrosine kinase and programmed cell death protein‐1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma
1小时前
已完结
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial
28天前
已关闭
Non-Hodgkin's Lymphoma in Couples
29天前
已完结
Markers of Response for the Antiangiogenic Agent Bevacizumab
1个月前
已完结
Targeted therapies for cutaneous T-cell lymphomas
3个月前
已关闭
Targeted therapies for cutaneous T-cell lymphomas
3个月前
已关闭
Therapeutic advances for Cutaneous T Cell Lymphoma
3个月前
已完结
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma
3个月前
已完结
Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma
3个月前
已完结
皖公网安备34019202002308
